A recent survey by GlobalData titled ‘The State of the Biopharmaceutical Industry 2024’ revealed that 44% of healthcare professionals surveyed globally say they are optimistic or very optimistic about the recovery of biotech financing in the next 12 months. This is a brightening of the outlook after private funding for biotech companies declined in 2022-2023.

In 2023, funding fell by 43.2 per cent compared to 2022 and 52.3 per cent compared to 2021, when the sector was hit with a hype that inflated – perhaps beyond measure – the pricing of many of its companies.

According to the report’s data, 607 US-based venture-backed companies are currently affected by the downturn in biotech funding, with more than 1,500 drugs at stake (including pre-clinical). Of these, about a third have not raised capital in the last three years.

The year 2024, however, is proving to be more favourable for biotechs, which are now the subject of cautious optimism.

Signs of recovery

According to an analysis by investment bank Jefferies, listed biotech companies have raised almost $10 billion in follow-on deals in the first two months of 2024. Their research reveals that the sector is on track to reach its highest quarterly funding peak in three years, aiming to surpass the $11 billion mark raised in follow-on deals in the first quarter of 2021.

The average size of funding rounds is also growing, having increased from $167m in January to $191m in February. Overall, in February alone, biotech and biopharmaceutical companies raised more than USD 38 billion.
According to the investment bank, this surge in funding is outlining an ‘industry recovery’.

For the complete article, visit the Making Pharma Industry website. Click here.